Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

A Rare Case of Primary Central Nervous System Lymphoma in an Adolescent Female Treated with High-Dose Methotrexate and Rituximab-Based Chemoimmunotherapy and Consolidation Whole Brain Radiotherapy.

Biswas A, Adhikari N, Bakhshi S, Gopinathan VR, Sharma MC.

Pediatr Neurosurg. 2019;54(1):57-65. doi: 10.1159/000495789. Epub 2019 Jan 22.

PMID:
30669145
2.
3.

A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.

Adhikari N, Biswas A, Gogia A, Sahoo RK, Garg A, Nehra A, Sharma MC, Bhasker S, Singh M, Sreenivas V, Chawla R, Joshi G, Kumar L, Chander S.

J Neurooncol. 2018 Aug;139(1):153-166. doi: 10.1007/s11060-018-2856-y. Epub 2018 Apr 9.

PMID:
29633112
4.

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.

Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).

Lancet Haematol. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6. Epub 2017 Oct 17.

PMID:
29054815
5.

Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.

Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A.

J Clin Oncol. 2013 Nov 1;31(31):3971-9. doi: 10.1200/JCO.2013.50.4910. Epub 2013 Oct 7.

6.

[Therapeutic management of central nervous system lymphomas in a single hematological institute].

Iványi JL, Marton E, Plander M, Gyánó G, Czumbil L, Tóth C.

Orv Hetil. 2009 Oct 18;150(42):1937-44. doi: 10.1556/OH.2009.28703. Hungarian.

PMID:
19812012
7.

Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.

Houillier C, Ghesquières H, Chabrot C, Soussain C, Ahle G, Choquet S, Nicolas-Virelizier E, Bay JO, Vargaftig J, Gaultier C, Touitou V, Martin-Duverneuil N, Cassoux N, Le Garff-Tavernier M, Costopoulos M, Faurie P, Hoang-Xuan K.

J Neurooncol. 2017 Jun;133(2):315-320. doi: 10.1007/s11060-017-2435-7. Epub 2017 Apr 21.

PMID:
28432587
8.

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).

Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6.

PMID:
27132696
9.

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.

Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM, Abrey LE.

J Clin Oncol. 2007 Oct 20;25(30):4730-5. Erratum in: J Clin Oncol. 2008 Jan 10;26(2):340.

PMID:
17947720
10.

Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.

Zhao D, Qian L, Shen J, Liu X, Mei K, Cen J, Wang Y, Li C, Ma Y.

J Cell Mol Med. 2014 Jun;18(6):1081-6. doi: 10.1111/jcmm.12252. Epub 2014 Mar 13.

11.

Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.

Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, Treseler P, O'Brien J, Shuman MA, Cha S, Damon LE, Rubenstein JL.

Clin Cancer Res. 2012 Feb 15;18(4):1146-55. doi: 10.1158/1078-0432.CCR-11-0625. Epub 2012 Jan 6.

12.

A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine.

Hattori K, Sakata-Yanagimoto M, Okoshi Y, Kato T, Kurita N, Yokoyama Y, Obara N, Takano S, Ishikawa E, Yamamoto T, Matsumura A, Hasegawa Y, Chiba S.

J Clin Exp Hematop. 2017 Oct 12;57(2):41-46. doi: 10.3960/jslrt.17012. Epub 2017 Aug 4.

13.

Successful Treatment of Bing-Neel Syndrome Accompanying Waldenström's Macroglobulinemia with R-MPV: A Case Report.

Kikukawa Y, Yamamura-Fujimoto A, Endo S, Miyagawa E, Kawano Y, Ueno S, Mitsuya H, Hata H, Okuno Y.

J Clin Exp Hematop. 2015;55(2):113-9. doi: 10.3960/jslrt.55.113.

14.

[Primary central nervous system lymphoma--a report of 32 cases with literature review].

Yi JQ, Lin TY, He YJ, Huang HQ, Xia ZJ, Xia YF, Xu RH, Guo Y, Guan ZZ.

Ai Zheng. 2006 Apr;25(4):476-80. Review. Chinese.

PMID:
16613684
15.

Rituximab with high-dose methotrexate in primary central nervous system lymphoma.

Kansara R, Shenkier TN, Connors JM, Sehn LH, Savage KJ, Gerrie AS, Villa D.

Am J Hematol. 2015 Dec;90(12):1149-54. doi: 10.1002/ajh.24204. Epub 2015 Nov 17.

16.

Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience.

Chanswangphuwana C, Rojnuckarin P, Cherdchoo N, Raiyawa T, Uaprasert N.

Hematology. 2018 Aug;23(7):385-390. doi: 10.1080/10245332.2017.1418610. Epub 2017 Dec 19.

PMID:
29256330
17.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
18.

A Case of Primary Central Nervous System Lymphoma Located at Brain Stem in a Child.

Kim J, Kim YZ.

Brain Tumor Res Treat. 2016 Oct;4(2):155-159. Epub 2016 Oct 31.

19.

Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma.

Sung KH, Lee EH, Kim YZ.

J Korean Med Sci. 2011 Apr;26(4):551-60. doi: 10.3346/jkms.2011.26.4.551. Epub 2011 Mar 28.

20.

High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.

Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J.

J Clin Oncol. 2006 Aug 20;24(24):3865-70. Epub 2006 Jul 24.

PMID:
16864853

Supplemental Content

Support Center